Organic Disturbances and Intellectual Disability DRG Reimbursement

Summary & Overview

Organic Disturbances and Intellectual Disability: Inpatient Reimbursement Overview

DRG 884 encompasses inpatient stays for organic disturbances of mental functioning and intellectual disability, focusing on acute management, evaluation, and support for cognitive disorders. Accurate classification into this Diagnosis-Related Group matters for inpatient reimbursement because it determines the Medicare prospective payment rate tied to the resources used during the hospitalization.

Organic Disturbances and Intellectual DisabilityDRG Organic Disturbances and Intellectual DisabilityDRG 884Diagnosis-Related GroupInpatient ReimbursementMedicareNeurologyPsychiatryGeriatrics

DRG 884 Overview

DRG 884 covers hospital admissions primarily for organic disturbances of mental functioning and intellectual disability, including delirium, dementia, and developmental disorders when the primary reason for inpatient care is management of these conditions. This Diagnosis-Related Group captures resource use tied to psychiatric assessment, medical evaluation for underlying causes, and supportive care needs. It matters for Medicare payment because classification into DRG 884 influences the prospective payment amount that hospitals receive for inpatient services centered on cognitive and intellectual impairments. Appropriate DRG assignment affects reimbursement tied to the intensity of diagnostic testing, medical comorbidities, and length of stay.

National Payment Rates

Across commercial payers in the table and chart below, negotiated allowed amounts for DRG 884 range from about $370 up to $42K, with the widest spread observed between the lowest and highest payer values (roughly $42K). Blue Cross Blue Shield, Anthem, Cigna, and Aetna show distinct median and upper-quartile positions that drive the overall range. Refer to the table and chart below for payer-specific percentiles and distribution details.

Mean Rates by Payer — National — DRG 884

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

In Alaska, payer rates for DRG 884 span from roughly $2.5K up to $44K across the reported payers, with Cigna showing the highest mean reimbursement and Blue Cross Blue Shield and Anthem the lowest mean levels. Cigna’s mean of $29K notably exceeds the other local payer means (~$19K) and represents the most significant deviation from typical national medians. See the table and chart below for payer-specific distributions.

Key Insights for Alaska

Highest payer: Cigna (mean $29K, max $44K) is the highest-paying among listed payers; Lowest payer: Blue Cross Blue Shield / Anthem (mean $19K, median $16K, min $2.5K) are the lowest-paying in AK.
The state exhibits a wide rate range from about $2.5K to $44K across payers; Cigna’s mean of $29K sits noticeably above the other local payers and above several national medians, indicating a meaningful positive deviation from national averages.

Clinical Trials

Acute behavioral and medical stabilization trials: studies designed to evaluate interventions for rapid stabilization of acute organic disturbances (for example, delirium due to metabolic encephalopathy or acute exacerbations of neurocognitive disorders) in hospitalized adults. These trials typically enroll patients admitted for sudden changes in cognition, consciousness, or behavior and test protocols such as multidisciplinary inpatient care bundles, medication-sparing strategies, or standardized diagnostic algorithms to shorten time to cognitive recovery and reduce complications. Findings are relevant to providers because they inform best practices for inpatient management, and to payers because successful stabilization protocols can reduce length of stay, prevent costly complications, and lower readmission risk.
Comparative effectiveness research on long-term management strategies for intellectual disability and chronic organic brain conditions: pragmatic trials or observational cohort studies comparing different care models (e.g., integrated inpatient-outpatient care pathways, community-supported discharge planning, or varied rehabilitation intensity) for patients with stable but persistent cognitive impairment or intellectual disability. These studies focus on functional outcomes, quality of life, resource utilization, and caregiver burden across diverse populations including children and adults with developmental disabilities or adults with chronic neurocognitive disorders. Results guide clinicians and health systems on which management approaches best preserve function and reduce avoidable inpatient utilization, helping payers optimize coverage for effective long-term supports and post-acute services.
Post-discharge outcomes and transitional care studies assessing readmission prevention and continuity of care for patients with organic disturbances or intellectual disability: prospective studies and quality-improvement trials testing interventions such as structured discharge planning, targeted caregiver education, telehealth follow-up, and coordination with community services. These investigations enroll recently discharged inpatients at high risk for relapse, medication-related complications, or care fragmentation and measure 30- to 90-day readmissions, emergency visits, adherence to follow-up, and caregiver strain. This research is pertinent to providers and payers because improved transitional care can reduce costly readmissions, improve patient safety, and inform reimbursement policies for post-acute support services.

Disorders of Personality and Impulse Control: Inpatient Reimbursement Overview

887-OTHER-MENTAL-DISORDER-DIAGNOSES

Other Mental Disorder Diagnoses: Inpatient Reimbursement Overview

880-ACUTE-ADJUSTMENT-REACTION-AND-PSYCHOSOCIAL-DYSFUNCTION

Acute Adjustment Reaction and Psychosocial Dysfunction: Inpatient Reimbursement Overview

886-BEHAVIORAL-AND-DEVELOPMENTAL-DISORDERS

Behavioral and Developmental Disorders: Inpatient Reimbursement Overview

881-DEPRESSIVE-NEUROSES

Depressive Neuroses: Inpatient Reimbursement Overview

882-NEUROSES-EXCEPT-DEPRESSIVE

Neuroses Except Depressive: Inpatient Reimbursement Overview

876-O-R-PROCEDURES-WITH-PRINCIPAL-DIAGNOSIS-OF-MENTAL-ILLNESS

O.R. Procedures with Principal Diagnosis of Mental Illness: Inpatient Reimbursement Overview

885-PSYCHOSES

Psychoses: Inpatient Reimbursement Overview

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$15K	$59K	$12K	21K